Clear All
11120 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
55513-0512-60 55513-0512 Sotorasib LUMAKRAS 240.0 mg/1 Chemotherapy RAS Inhibitor KRAS G12C Oral Jun 27, 2024 In Use
60429-0265-01 60429-0265 Hydroxyurea Hydroxyurea 500.0 mg/1 Chemotherapy Miscellaneous Agent Antimetabolite/Organooxygen Oral Oct 26, 2012 Dec 31, 2024 In Use
60505-3816-03 60505-3816 Dasatinib Dasatinib 80.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sep 3, 2024 In Use
51285-0369-01 51285-0369 Methotrexate Trexall 15.0 mg/1 Chemotherapy Antimetabolite Folic Acid Analog Oral May 3, 2001 In Use
72064-0210-60 72064-0210 pralsetinib GAVRETO 100.0 mg/1 Chemotherapy Enzyme Inhibitor RET, DDR1, TRKC, FLT3, JAK1/2, TRKA, VEGFR2, PDGFRB, FGFR1 Oral Sep 4, 2020 Apr 30, 2022 No Longer Used
68001-0350-68 68001-0350 GEMCITABINE GEMCITABINE 100.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous May 25, 2018 May 26, 2018 In Use
69097-0368-40 69097-0368 Azacitidine Azacitidine 100.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Intravenous, Subcutaneous May 4, 2018 In Use
68001-0539-41 68001-0539 Pemetrexed disodium Pemetrexed 500.0 mg/20mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous Jun 24, 2022 In Use
62175-0242-24 62175-0242 Temozolomide Temozolomide 100.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Feb 10, 2016 In Use
31722-0264-30 31722-0264 ERLOTINIB ERLOTINIB 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral May 24, 2024 In Use
69189-0383-01 69189-0383 Cyclophosphamide Cyclophosphamide 50.0 mg/1 Chemotherapy Alkylating Agent Nitrogen Mustard Oral Apr 23, 2015 May 24, 2017 No Longer Used
66435-0410-05 66435-0410 Topotecan Hydrochloride Topotecan Hydrochloride 4.0 mg/4mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous Dec 2, 2010 Oct 31, 2014 No Longer Used
69315-0164-01 69315-0164 Hydroxyurea Hydroxyurea 500.0 mg/1 Chemotherapy Miscellaneous Agent Antimetabolite/Organooxygen Oral Jul 9, 2020 In Use
69448-0001-05 69448-0001 Mitomycin Mutamycin 5.0 mg/10mL Chemotherapy Antitumor Antibiotic Alkylating Agent/ Mitomycin Intravenous Jul 25, 2017 In Use
45963-0623-57 45963-0623 Gemcitabine Gemcitabine 38.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Apr 12, 2016 Sep 30, 2020 No Longer Used
58468-0100-01 58468-0100 Clofarabine Clolar 1.0 mg/mL Chemotherapy Antimetabolite Purine Analog Intravenous Dec 28, 2004 Mar 31, 2013 No Longer Used
45963-0624-58 45963-0624 Gemcitabine Gemcitabine 38.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Apr 12, 2016 Jan 31, 2021 No Longer Used
72205-0007-92 72205-0007 Capecitabine Capecitabine 500.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Jul 21, 2018 In Use
00093-7600-41 00093-7600 Temozolomide Temozolomide 20.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Aug 12, 2013 Jan 31, 2019 In Use
45963-0636-60 45963-0636 Gemcitabine Gemcitabine 38.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Apr 12, 2016 Sep 30, 2020 No Longer Used
45963-0637-49 45963-0637 Oxaliplatin Oxaliplatin 5.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Aug 3, 2018 Feb 29, 2020 No Longer Used
45963-0638-58 45963-0638 Oxaliplatin Oxaliplatin 5.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Aug 3, 2018 Feb 29, 2020 No Longer Used
00093-7630-56 00093-7630 Imatinib Mesylate Imatinib Mesylate 400.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Aug 4, 2016 In Use
47335-0082-50 47335-0082 Doxorubicin Hydrochloride LIPODOX 2.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravenous Feb 9, 2012 May 29, 2015 In Use
72603-0104-01 72603-0104 Cyclophosphamide Cyclophosphamide 500.0 mg/25mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous, Oral May 10, 2019 In Use

Found 11120 results — Export these results